🔴 Kura Oncology is trading 6.3% down in pre-market — reason remains unclear

Kura Oncology is trading 6.3% lower at $10.12 before the September 30, 2026 open; the reason for the decline remains unclear.

• Supplied price context lists the previous close at $10.80.
• The September 29 announcement highlighted Caspian Therapeutics’ KO-7246 diabetes program, but available information does not link it to the decline.
• The reported insider sale was a tax-withholding sell-to-cover transaction, not a clear catalyst; major indices were near flat.